Navigation Links
Pharmasset Reports Fiscal Year End 2008 Financial Results
Date:12/11/2008

aive and treatment experienced HCV patients. In addition, the company was issued a US patent covering R7128.

Results from the 28 day study were presented at the recent American Association for the Study of Liver Diseases (AASLD) that demonstrated that R7128 combined with the standard of care (pegylated interferon and ribavirin) provided significant short-term antiviral activity with safety and tolerability comparable to the standard of care alone. Results from the 500mg BID, 1000mg BID, 1500mg BID dose cohorts in 81 treatment-naive patients chronically infected with HCV genotype 1 indicated rapid virological response (RVR) rates of 30% (6 of 20), 88% (22 of 25) and 85% (17 of 20), respectively compared to 19% (3 of 16) in the control group. Further results in genotype 2 and 3, non responder patients treated with 1500mg BID generated RVR rate of 90% (18 of 20) versus 60% (3 of 5) in the control group. Across all studies, safety and tolerability of R7128 combined with peginterferon and ribavirin was similar to the standard of care alone.

Based on these results and other data, Pharmasset's partner, Roche, plans to move R7128 into a phase 2b trial in HCV-1 infected patients in the first calendar quarter of 2009. Pharmasset has submitted the necessary briefing documents to the FDA and both Roche and Pharmasset plan to meet with the agency in early January to review the preclinical and clinical data and to discuss the phase 2b design and future studies.

In addition to planning for phase 2b, Roche initiated the INFORM-1 trial, a potentially ground-breaking study to investigate the activity of a combination of two oral antiviral molecules in the absence of interferon. The study began in November 2008, and will investigate the combination of Pharmasset's R7128 with InterMune's R7227, a protease inhibitor. The first cohort of patients has been enrolled and preliminary results from this study are expected in fi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
3. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
4. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
5. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Pharmasset Receives Notice of Allowance
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... N.J. , June 18, 2013  Actavis, Inc. (NYSE: ... Actavis") has filed with the U.S. Securities and Exchange Commission ... Actavis, proposed acquisition of Warner Chilcott plc (NASDAQ: ... of Actavis and Warner Chilcott (the "Form S-4"). ... and Warner Chilcott have entered into a definitive ...
(Date:6/18/2013)... N.Y. , June 18, 2013  Millennium ... it has entered into an exclusive 25-year Supply ... regions with eWellness Corporation ("EWC") for its Distance ... easy to use physical therapy program is a ... and cardiovascular disease," said Chris Amandola , ...
(Date:6/18/2013)... , June 18, 2013  Women are frequently the ... unfortunately they often do not give the same priority ... kept information from their doctor because they were too ... to a recent survey conducted by Allergan and endorsed ... to bringing education, funding and research to the field ...
Breaking Medicine Technology:Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 2New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 3New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 4New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 5New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 6New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 7New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 8New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 9
(Date:6/19/2013)... Recovery Associates, through its multiple therapeutic ... treatment, helping men and women break free from the ... is a stimulant named for the crystalline structure it ... smoked, but it can also be injected or taken ... labs using common household ingredients and over-the-counter medicine. Crystal ...
(Date:6/19/2013)... June 19, 2013 The Semi Truck ... member is a innocent victim of a serious accident involving ... or any rural area in the US, we are urging ... response, because time really is of these essence, and it ... of truck accident legal experts, and their investigators in your ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Middle market ... 2013 across all industries as cash rich buyers seek ... differences across industries, all M&A transactions have a good ... diligence to verify the history and quality of the ... , But when due diligence involves a middle ...
(Date:6/18/2013)... Kent, WA (PRWEB) June 18, 2013 As a sponsor ... Saggau and the whole team at Lake Meridian Chiropractic want you to ... have many fond memories of the event and are excited to be ... for 24 years. We've always loved going to the Kent Splash ... year, so it only made sense to financially support this fun day.” ...
(Date:6/18/2013)... An apple a day might really ... diagnosed with breast cancer, she chose a different method ... Gave Myself Cancer, I Can Take It Away!: Alternatives ... Beauregard explains how changing her physical, mental and emotional ... been made to feel fearful when diagnosed with a ...
Breaking Medicine News(10 mins):Health News:Crystal Meth Addiction Treatment and Crystal Meth Drug Rehab Announced by Recovery Associates 2Health News:The Semi Truck Accident Victims Center Urges Families Of Innocent Victims Of A Semi Truck Accident In Montana, Idaho Or Wyoming To Call Them For An On The Spot Response 2Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3Health News:Lake Meridian Chiropractic of Kent, WA to Sponsor the Fireworks Finale at 15th Annual Fourth of July Splash 2Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2
... which could presumably play a major role in the development// ... down after examination of tumor tissue from 53 breast cancer ... which confirmed the findings. This new discovery could provide ... haunting women. ,Our improved understanding of cancer biology and genetic ...
... Japan Thursday announced a grant of $7 million for ... grant assistance would enable the Sardar Vallavbhai Patel Postgraduate ... facilities and effectively contribute towards dispensation of healthcare to ... embassy. , ,Notes concerning the project were signed ...
... doses of vitamins and minerals// are allowing themselves to ... researchers. , ,No one knows what adverse long ... the levels promoted by some alternative therapists and celebrities, ... middle-class professionals who turned to vitamins and minerals in ...
... elderly population may not be checked regularly for chronic ... in them. ,Researchers from Tufts-New England Medical Center, ... of the American Society of Nephrology that there remained ... for the geriatric patients with this health condition., ...
... on hopes for a new drug to treat women with //low ... more studies to be done on the Intrinsa patch made by ... effects the drug may induce, the Los Angeles Times reported. , ... to restore healthy sexual appetites to women struggling with low desire., ...
... attempted to commit suicide repeatedly can now be treated ... found to give better results than the other treatments ... findings were published in the current issue of JAMA. ... conducted a randomized controlled trial to determine whether a ...
Cached Medicine News:Health News:Vitamin Supplements - Good, The Bad And The Ugly 2Health News:Vitamin Supplements - Good, The Bad And The Ugly 3Health News:Geriatric Patients With Chronic Kidney Disease May Not Be Treated Properly 2Health News:FDA Diminish Hopes On ‘Female Viagra 2Health News:FDA Diminish Hopes On ‘Female Viagra 3Health News:Suicidal Tendencies May Be Treated With Cognitive Therapy 2
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... 4F, 5F, and 6F ... is ideal for coronary ... state-of-the-art technology and proprietary ... better responsiveness, optimal torque, ...
Medicine Products: